The global pigmentation disorders treatment market size is expected to reach around US$ 9,368.6 Mn in 2026 and is anticipated to expand at a CAGR of more than 6.7% from 2019 to 2026. Several factors such as augmented adoption of lasers in pigmentation disorders treatment, decrease in social taboos boosting acceptance of pigmentation disorders treatment measures, and increase in prevalence of pigmentation-related disorders are driving the global pigmentation disorders treatment market.
The report analyzes and forecasts the pigmentation disorders treatment market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of pigmentation disorders treatment, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major pigmentation disorders treatment companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of pigmentation disorders treatment upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of pigmentation disorders treatment and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global pigmentation disorders treatment market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the pigmentation disorders treatment market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of pigmentation disorders treatment market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in Report
The report profiles major players operating in the global pigmentation disorders treatment market in terms of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in this report are Bayer AG, ALLERGAN, Galderma S.A., SkinCeuticals, Pierre Fabre, EpiPharm AG, RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC, and Vivier Pharma.
The global pigmentation disorders treatment market has been segmented as follows:
Pigmentation Disorders Treatment Market, by Treatment
Pigmentation Disorders Treatment Market, by Disease Indication
Pigmentation Disorders Treatment Market, by End-user
Pigmentation Disorders Treatment Market, by Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Section 01 Preface
1.1 Report Scope and Market Segmentation
1.2 Research Highlights
Section 02 Assumptions and Research Methodology
2.1 Assumptions
2.2 Research Methodology
Section 03 Executive Summary
3.1 Global Pigmentation Disorders Treatment Market Size (US$ Mn)
3.2 Global Pigmentation Disorders Treatment Market Snapshot, 2017
3.3 Global Pigmentation Disorders Treatment Market: Opportunity Map
Section 04 Market Overview
4.1 Overview
4.2 Global Pigmentation Disorders Treatment Market Size (US$ Mn) Forecast, 2016–2026
4.3 Global Pigmentation Disorders Treatment Market Outlook
4.4 Global Pigmentation Disorders Treatment Market: Porter’s Five Forces Analysis
4.5 Pigmentation Disorders Treatment Market: Pipeline Analysis
4.6 Key Partnership & Acquisitions
4.7 Policies and Regulations, by Region
4.8 Disease Prevalence and Incidence Rate Globally
Section 05 Market Dynamics
5.1 Drivers
5.2 Restraints
5.3 Opportunity Analysis
5.4 Opportunities
5.5 Trends
Section 06 Pigmentation Disorders Treatment Market Analysis, by Treatment
6.1 Introduction
6.2 Global Pigmentation Disorders Treatment Market Value Share Analysis, by Treatment
6.3 Pigmentation Disorders Treatment Market Analysis, by Treatment
6.3.1 Topical Drugs
6.3.2 Laser Therapy
6.3.3 Chemical Peels
6.3.4 Microdermabrasion
6.3.5 Phototherapy
6.3.6 Others
6.4 Pigmentation Disorders Treatment Market Attractiveness Analysis, by Treatment
Section 07 Pigmentation Disorders Treatment Market Analysis, by Disease Indication
7.1 Introduction
7.2 Global Pigmentation Disorders Treatment Market Value Share Analysis, by Disease Indication
7.3 Pigmentation Disorders Treatment Market Analysis, by Disease Indication
7.3.1 Global Pigmentation Disorders Treatment Market Analysis, by Hypopigmentation
7.3.1.1 Vitiligo
7.3.1.2 Albinism
7.3.1.3 Others
7.3.2 Global Pigmentation Disorders Treatment Market Analysis, by Hyperpigmentation
7.3.2.1 Melasma
7.3.2.2 Post-inflammatory Pigmentation
7.3.2.3 Solar Lentigines
7.3.2.4 Others
7.4 Pigmentation Disorders Treatment Market Attractiveness Analysis, by Disease Indication
7.5 Pigmentation Disorders Treatment Market Attractiveness Analysis, by Hypopigmentation
7.6 Pigmentation Disorders Treatment Market Attractiveness Analysis, by Hyperpigmentation
Section 08 Pigmentation Disorders Treatment Market Analysis, by End-user
8.1 Introduction
8.2 Global Pigmentation Disorders Treatment Market Value Share Analysis, by End-user
8.3 Pigmentation Disorders Treatment Market Analysis, by End-user
8.3.1 Hospitals
8.3.2 Aesthetic Clinics & Dermatology Centers
8.3.3 Others
8.4 Pigmentation Disorders Treatment Market Attractiveness Analysis, by End-user
Section 09 Pigmentation Disorders Treatment Market Analysis, by Region
9.1 Global Pigmentation Disorders Treatment Market Snapshot, by Country
9.2 Global Pigmentation Disorders Treatment Market Value Share Analysis, by Region
9.3 Pigmentation Disorders Treatment Market Forecast, by Region
9.3.1 North America
9.3.2 Europe
9.3.3 Asia Pacific
9.3.4 Latin America
9.3.5 Middle East & Africa
9.4 Pigmentation Disorders Treatment Market Attractiveness Analysis, by Region
Section 10 North America Pigmentation Disorders Treatment Market Analysis
10.1 Key Findings
10.2 North America Pigmentation Disorders Treatment Market Overview
10.3 North America Market Value Share Analysis, by Treatment
10.4 North America Market Forecast, by Treatment
10.4.1 Topical Drugs
10.4.2 Laser Therapy
10.4.3 Chemical Peels
10.4.4 Microdermabrasion
10.4.5 Phototherapy
10.4.6 Others
10.5 North America Market Value Share Analysis, by Disease Indication
10.6 North America Market Forecast, by Disease Indication
10.6.1 North America Market Forecast, by Hypopigmentation
10.6.1.1 Vitiligo
10.6.1.2 Albinism
10.6.1.3 Others
10.6.2 North America Market Forecast, by Hyperpigmentation
10.6.2.1 Melasma
10.6.2.2 Post-inflammatory Pigmentation
10.6.2.3 Solar Lentigines
10.6.2.4 Others
10.7 North America Market Value Share Analysis, by End-user
10.8 North America Market Forecast, by End-user
10.8.1 Hospitals
10.8.2 Aesthetic Clinics & Dermatology Centers
10.8.3 Others
10.9 Market Analysis, by Country
10.10 Market Value Share Analysis, by Country
10.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
10.11.1 U.S.
10.11.2 Canada
10.12 Market Attractiveness Analysis
10.12.1 By Treatment
10.12.2 By Disease Indication
10.12.3 By Disease Hypopigmentation
10.12.4 By Disease Hyperpigmentation
10.12.5 By End-user
10.12.6 By Country
Section 11 Europe Pigmentation Disorders Treatment Market Analysis
11.1 Key Findings
11.2 Europe Pigmentation Disorders Treatment Market Overview
11.3 Europe Market Value Share Analysis, by Treatment
11.4 Europe Market Forecast, by Treatment
11.4.1 Topical Drugs
11.4.2 Laser Therapy
11.4.3 Chemical Peels
11.4.4 Microdermabrasion
11.4.5 Phototherapy
11.4.6 Others
11.5 Europe Market Value Share Analysis, by Disease Indication
11.6 Europe Market Forecast, by Disease Indication
11.6.1 Europe Market Forecast, by Hypopigmentation
11.6.1.1 Vitiligo
11.6.1.2 Albinism
11.6.1.3 Others
11.6.2 Europe Market Forecast, by Hyperpigmentation
11.6.2.1 Melasma
11.6.2.2 Post-inflammatory Pigmentation
11.6.2.3 Solar Lentigines
11.6.2.4 Others
11.7 Europe Market Value Share Analysis, by End-user
11.8 Europe Market Forecast, by End-user
11.8.1 Hospitals
11.8.2 Aesthetic Clinics & Dermatology Centers
11.8.3 Others
11.9 Market Analysis, by Country
11.10 Market Value Share Analysis, by Country
11.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
11.11.1 Germany
11.11.2 France
11.11.3 U.K.
11.11.4 Italy
11.11.5 Spain
11.11.6 Rest of Europe
11.12 Market Attractiveness Analysis
11.12.1 By Treatment Type
11.12.2 By Disease Indication
11.12.3 By Disease Hypopigmentation
11.12.4 By Disease Hyperpigmentation
11.12.5 By End-user
11.12.6 By Country
Section 12 Asia Pacific Pigmentation Disorders Treatment Market Analysis
12.1 Key Findings
12.2 Asia Pacific Pigmentation Disorders Treatment Market Overview
12.3 Asia Pacific Market Value Share Analysis, by Treatment
12.4 Asia Pacific Market Forecast, by Treatment
12.4.1 Topical Drugs
12.4.2 Laser Therapy
12.4.3 Chemical Peels
12.4.4 Microdermabrasion
12.4.5 Phototherapy
12.4.6 Others
12.5 Asia Pacific Market Value Share Analysis, by Disease Indication
12.6 Asia Pacific Market Forecast, by Disease Indication
12.6.1 Asia Pacific Market Forecast, by Hypopigmentation
12.6.1.1 Vitiligo
12.6.1.2 Albinism
12.6.1.3 Others
12.6.2 Asia Pacific Market Forecast, by Hyperpigmentation
12.6.2.1 Melasma
12.6.2.2 Post-inflammatory Pigmentation
12.6.2.3 Solar Lentigines
12.6.2.4 Others
12.7 Asia Pacific Market Value Share Analysis, by End-user
12.8 Asia Pacific Market Forecast, by End-user
12.8.1 Hospitals
12.8.2 Aesthetic Clinics & Dermatology Centers
12.8.3 Others
12.9 Market Analysis, by Country
12.10 Market Value Share Analysis, by Country
12.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
12.11.1 China
12.11.2 Japan
12.11.3 India
12.11.4 Australia & New Zealand
12.11.5 Rest of Asia Pacific
12.12 Market Attractiveness Analysis
12.12.1 By Treatment
12.12.2 By Disease Indication
12.12.3 By Disease Hypopigmentation
12.12.4 By Disease Hyperpigmentation
12.12.5 By End-user
12.12.6 By Country
Section 13 Latin America Pigmentation Disorders Treatment Market Analysis
13.1 Key Findings
13.2 Latin America Pigmentation Disorders Treatment Market Overview
13.3 Latin America Market Value Share Analysis, by Treatment
13.4 Latin America Market Forecast, by Treatment
13.4.1 Topical Drugs
13.4.2 Laser Therapy
13.4.3 Chemical Peels
13.4.4 Microdermabrasion
13.4.5 Phototherapy
13.4.6 Others
13.5 Latin America Market Value Share Analysis, by Disease Indication
13.6 Latin America Market Forecast, by Disease Indication
13.6.1 Latin America Market Forecast, by Hypopigmentation
13.6.1.1 Vitiligo
13.6.1.2 Albinism
13.6.1.3 Others
13.6.1 Latin America Market Forecast, by Hyperpigmentation
13.6.2.1 Melasma
13.6.2.2 Post-inflammatory Pigmentation
13.6.2.3 Solar Lentigines
13.6.2.4 Others
13.7 Latin America Market Value Share Analysis, by End-user
13.8 Latin America Market Forecast, by End-user
13.8.1 Hospitals
13.8.2 Aesthetic Clinics & Dermatology Centers
13.8.3 Others
13.9 Market Analysis, by Country
13.10 Market Value Share Analysis, by Country
13.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
13.11.1 Brazil
13.11.2 Mexico
13.11.3 Rest of Latin America
13.12 Market Attractiveness Analysis
13.12.1 By Treatment
13.12.2 By Disease Indication
13.12.3 By Disease Hypopigmentation
13.12.4 By Disease Hyperpigmentation
13.12.5 By End-user
13.12.6 By Country
Section 14 Middle East & Africa Pigmentation Disorders Treatment Market Analysis
14.1 Key Findings
14.2 Middle East & Africa Pigmentation Disorders Treatment Market Overview
14.3 Middle East & Africa Market Value Share Analysis, by Treatment
14.4 Middle East & Africa Market Forecast, by Treatment
14.4.1 Topical Drugs
14.4.2 Laser Therapy
14.4.3 Chemical Peels
14.4.4 Microdermabrasion
14.4.5 Phototherapy
14.4.6 Others
14.5 Middle East & Africa Market Value Share Analysis, by Disease Indication
14.6 Middle East & Africa Market Forecast, by Disease Indication
14.6.1 Middle East & Africa Market Forecast, by Hypopigmentation
14.6.1.1 Vitiligo
14.6.1.2 Albinism
14.6.1.3 Others
14.6.2 Middle East & Africa Market Forecast, by Hyperpigmentation
14.6.2.1 Melasma
14.6.2.2 Post-inflammatory Pigmentation
14.6.2.3 Solar Lentigines
14.6.2.4 Others
14.7 Middle East & Africa Market Value Share Analysis, by End-user
14.8 Middle East & Africa Market Forecast, by End-user
14.8.1 Hospitals
14.8.2 Aesthetic Clinics & Dermatology Centers
14.8.3 Others
14.9 Market Analysis, by Country
14.10 Market Value Share Analysis, by Country
14.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
14.11.1 GCC Countries
14.11.2 South Africa
14.11.3 Rest of Middle East & Africa
14.12 Market Attractiveness Analysis
14.12.1 By Treatment
14.12.2 By Disease Indication
14.12.3 By Disease Hypopigmentation
14.12.4 By Disease Hyperpigmentation
14.12.5 By End-user
14.12.6 By Country
Section 15 Competition Landscape
15.1 Competition Matrix
15.2 Pigmentation Disorders Treatment Market Share Analysis, by Company (2017)
15.3 Company Profiles
15.3.1 Bayer AG
15.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2 Product Portfolio
15.3.1.3 SWOT Analysis
15.3.1.4 Strategic Overview
15.3.1.5 Financial Overview
15.3.2 ALLERGAN
15.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2 Product Portfolio
15.3.2.3 SWOT Analysis
15.3.2.4 Strategic Overview
15.3.2.5 Financial Overview
15.3.3 Galderma S.A. (Nestle Skin Health S.A)
15.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2 Product Portfolio
15.3.3.3 SWOT Analysis
15.3.3.4 Strategic Overview
15.3.4 SkinCeuticals
15.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2 Product Portfolio
15.3.4.3 SWOT Analysis
15.3.4.4 Strategic Overview
15.3.5 Pierre Fabre
15.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2 Product Portfolio
15.3.5.3 SWOT Analysis
15.3.5.4 Strategic Overview
15.3.5.5 Financial Overview
15.3.6 EpiPharm AG
15.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2 Product Portfolio
15.3.6.3 SWOT Analysis
15.3.6.4 Strategic Overview
15.3.7 RXi Pharmaceuticals Corporation
15.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2 Product Portfolio
15.3.7.3 SWOT Analysis
15.3.7.4 Strategic Overview
15.3.7.5 Financial Overview
15.3.8 Obagi Cosmeceuticals LLC (Obagi medical)
15.3.8.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2 Product Portfolio
15.3.8.3 SWOT Analysis
15.3.8.4 Strategic Overview
15.3.9 Vivier Pharma
15.3.9.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2 Product Portfolio
15.3.9.3 SWOT Analysis
15.3.9.4 Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers